

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Glycorex Transplantation AB	
Application No./Patent No.: 09/750,280	Filed/Issue Date: 29 December 2000
Entitled: Trifunctional Reagent for Conjugation to a Biomolecule	

Glycorex Transplantation AB (Assignee), a Company of Sweden (Entity type)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is 100 %

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel/Frame , on .

**OR**

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

**Assignment: 1**

**Reel/Frame:** 011716/0234

**Recorded:** 04/18/2001

**Pages:** 3

**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

**Assignors:** WILBUR, D. SCOTT

**Exec Dt:** 01/20/2001

SANDBERG, BENGT E.B.

**Exec Dt:** 02/12/2001

**Assignees:** DEPARTMENT OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON

MAILSTOP 358750

2121 NORTH 35TH STREET

SEATTLE, WASHINGTON 98103

MITRA MEDICAL TECHNOLOGY AB OF IDEON RESEARCH PARK

MAILSTOP 358750

2121 NORTH 35TH STREET

223 70 LUND, SWEDEN

**Correspondent:** SMITH, GAMBRELL & RUSSELL, LLP

MICHAEL K. CARRIES

1850 M. ST NW (STE 800)

WASHINGTON, DC 20036

**Assignment: 2**

**Reel/Frame:** 020559/0045

**Recorded:** 02/26/2008

**Pages:** 6

**Conveyance:** CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

**Assignor:** MITRA MEDICAL TECHNOLOGY AB

**Exec Dt:** 10/20/2004

**Assignee:** MITRA MEDICAL AB

FORSKARBYN IDEON

LUND, SWEDEN 223 70

**Correspondent:** SWANSON & BRATSCHUN, LLC

8210 SOUTHPARK TERRACE

LITTLETON, CO 80120

**Assignment: 3**

**Reel/Frame:** 020510/0725

**Recorded:** 02/14/2008

**Pages:** 5

**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

**Assignor:** MITRA MEDICAL AB

**Exec Dt:** 01/14/2008

**Assignee:** BIOTECH IGG AB

SCHEELEVAGEN 17

LUND, SWEDEN S-223 70

**Correspondent:** SWANSON & BRATSCHUN, LLC

8210 SOUTHPARK TERRACE


LITTLETON, CO 80120


**Assignment: 4**

From Biotech IGG AB to Glycorex Transplantation AB via a Patent Transfer Agreement dated 12 November 2008 which is attached herewith.

[NOTE: A separate copy (*i.e.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Name:	Suzannah K. Sundby		
Signature:		Date:	7 July 2009
Title:	Attorney of Record, Reg. No. 43,172	Telephone:	202-263-4332



## PATENT TRANSFER AGREEMENT

Biotech-IgG AB, company registration No. 556713-5818, located at Forskningsbyn Ideon, 223 70 Lund, Sweden, was declared bankrupt by the District Court of Lund, Sweden, on 26<sup>th</sup> June 2008. The court appointed Mr Bo Svensson at the lawfirm Advokatfirman Glimstedt as a official receiver in the bankruptcy. The bankruptcy estate of Biotech-IgG AB in bankruptcy, represented by its official receiver, has now entered the following agreement with Glycorex Transplantation AB.

**Biotech-IgG AB's bankruptcy estate**, located at c/o Advokatfirman Glimstedt, P O Box 1246, 221 05 Lund, Sweden – hereinafter referred to as “the Seller” –

and,

**Glycorex Transplantation AB**, company registration No. 556519-7372, located at Sölvegatan 41, 223 70 Lund, Sweden – hereinafter referred to as “the Buyer” –

has agreed as follows.

The Seller hereby sells and assigns to the Buyer the patent and patent applications listed in Enclosure A - hereinafter referred to as “the Patent Rights”. The assignment also includes all assignable rights derived from the Patent Rights including, without limitation, the right to the claimed inventions, the right to claim priority, and the right to file divisional patent application and take similar actions.

The Buyer shall be responsible for the recording of the assignment of the Patent Rights. The Seller's obligations in this respect is limited to, at the request of the Buyer, without any cost for the Buyer, signing all documents prepared by the Buyer and reasonably required in order to record the assignment with the appropriate authorities and to do such other acts as necessary to give full effect to the terms of this agreement.




ADVOKATFIRMAN  
GLIMSTEDT


This agreement shall be governed by Swedish law. Any dispute in connection with this Agreement shall be referred to the District Court of Lund, Sweden.

Lund 12<sup>th</sup> November 2008

Biotech-IgG AB's bankruptcy estate

  
\_\_\_\_\_  
Bo Svensson  
Official Receiver

Glycorex Transplantation AB

  
\_\_\_\_\_  
/Kurt Nilsson/  
President and CEO

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Req. data Duration	Filing date Reg. date	Appl. No Reg. No	File No Country	Handl by	Status
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2008-12-12 2023-12-12	2003-12-12	2003 267131	21020170 Australia	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-AU	2008-12-12 2023-12-12	2003-12-12	2 508 103	21020172 Canada	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-CA		2003-12-12	2003380108743.0	21020173 China	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-CN	2008-12-31 2023-12-12	2003-12-12	03781200.5	21020175 European Patent Office	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	168062	21020177 Israel	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-IL		2003-12-12	01217(CHENP200)	21020176 India	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	2004-550221	21020178 Japan	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-JP		2003-12-12	2005-7010611	21020174 Republic of Korea	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	PA/AZ055006308	21020179 Mexico	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-MX	2008-12-31 2023-12-12	2003-12-12	2005 2642	21020180 Norway	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-NO		2003-12-12	P 377 213	21020181 Poland	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	2005122033	21020181 Russian Federation	DH	Pending
Patent Normal via PCT National Phase	ANTI LYMPHOMA-PC-RU						

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Ren date Duration	Filing date Reg. date	App. No. Reg. No.	File No. Country	Handl by	Status
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	10538 659	21020182 United States of America	DH	Pending
Patent Normal via PCT National Phase	ANTI LYNPHOMA-PC-US						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2008-07-07 2019-07-07	1999-07-07	12 335 735	2002573 Canada	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-PC-CA						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2008-07-07 2019-07-07	1999-07-07	59835251.1	2002576 European Patent Office	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-PC-EP						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONCOLOGY, UNIV		1989-07-07	2000-558695	2002574 Japan	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-PC-JP						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2008-07-07 2019-07-07	1999-07-07	2001 0021	2002575 Norway	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-PC-NO						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONCOLOGY, UNIV		1999-07-07	09/750 280	2002572 United States of America	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-PC-US						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; OFFICE OF TECHNOLOGY TRANSFER, UNIVER		1998-07-07	11/193 956	21022674 United States of America	DH	Pending
Patent Normal via PCT National Phase	BIOMOLECULES-P-US-CON						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONCOLOGY, UNIV		2001-06-16	09/081 243	21000270 United States of America	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVE-P-US						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2009-06-18 2021-06-18	2001-05-10 2005-10-13	2001 274761	21001348 Australia	DH	Registered
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-AU						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2009-06-18 2021-06-18	2001-05-18	12 412 495	21001350 Canada	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-CA						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONCOLOGY, UNIV		2001-06-18	01 812454.2	21001351 China	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-CN						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ON	2009-06-30 2021-06-18	2001-05-18	101941404.4	21001352 European Patent Office	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-EP						

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Ren. date Duration	Filing date Reg. date	App. No Reg. No		File No Country	Handl by	Status
				Classes				
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC	2011-06-18 2021-06-18	2001-05-18 2008-04-07	153 449 153 449		21001354 Israel	DH	Registered
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-IL							
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC		2001-08-18	2002-510039		21001355 Japan	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-JP							
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC		2001-05-18	2002 012438		21001356 Mexico	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-MX							
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC	2009-06-30 2021-06-18	2001-05-18	2002 5931		21001357 Norway	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-NO							
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC		2001-06-18	P 389 328		21001358 Poland	DH	Pending
Patent Normal via PCT National Phase	BIOTIN DERIVATIVES-PC-PL							
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB; DEPARTMENT OF RADIATION ONC		2001-06-18	100311 150		21001360 United States of America	DH	Pending
Patent EP Validation	BIOTIN DERIVATIVES-PC-US							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 P692 28802.3		2982350 Germany	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-DE							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 567 514		2982341 Denmark	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-DK							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 567 514		2982347 Spain	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-ES							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 567 514		2982342 France	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-FR							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 567 514		2982348 United Kingdom	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-GB							
Patent EP Validation	LINDGREN, LARS; NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1999-03-31	92903020.3 567 514		2982343 Italy	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-IT							

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Ren. date Duration	Filing date Reg. date	Appl. No Reg. No Classes	File No Country	Hand by	Status
Patent EP Validation	LINDGREN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1996-02-31	920930203 567 514	2082345 Netherlands	DH	Registered
	BLODBEHANDLING-EP-HL						
Patent EP Validation	LINDGREN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1996-03-31	920930203 567 514	2082349 Sweden	DH	Registered
	BLODBEHANDLING-EP-SE						
Patent Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUNE	2009-01-15 2012-01-15	1992-01-15 2004-06-08	2 100 256 2 100 256	2831307 Canada	DH	Registered
	BLODBEHANDLING-P-CA						
Patent Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUNE	2009-06-12 2012-01-15	1992-01-15 2003-09-12	503119 92 3 471 362	2031309 Japan	DH	Registered
	BLODBEHANDLING-P-JP						
Patent Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2009-12-26 2018-06-26	1992-01-15 2001-06-26	050 047 6 261 394	2031308 United States of America	DH	Registered
	BLODBEHANDLING-P-US						
Patent Normal	MITRA MEDICAL TECHNOLOGY AB	2012-12-12	1990-09-02 1995-12-12	07562 009 5 474 772	2002334 United States of America	DH	Registered
	CV-0038-P-US-I						
Patent Normal	MITRA MEDICAL TECHNOLOGY AB	2011-10-04 2012-12-12	1995-05-04 2000-04-04	081434 889 6 046 225	2002337 United States of America	DH	Registered
	CV-0038-P-US-II						
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	90800077.1 P089 120B6.9	21006851 Germany	BAM	Registered
	KOLONNEHUS-EP-DE						
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	90800077.1 1 049 499	21006849 Denmark	BAM	Registered
	KOLONNEHUS-EP-DK						
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	90800077.1 1 049 499	21006864 Spain	BAM	Registered
	KOLONNEHUS-EP-ES						
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	90800077.1 1 049 499	21006950 France	BAM	Registered
	KOLONNEHUS-EP-FR						
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	90800077.1 1 049 499	21006966 United Kingdom	BAM	Registered
	KOLONNEHUS-EP-GB						



Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Ren/date Duration	Filing date Reg. date	Appl. No Reg. No	Class	File No Country	Hand by	Status
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03794388.3 1 551 464		21034668 France	ATX	Registered
	NEW COMPOSITION-EP-FR							
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03754388.3 1 551 464		21034667 United Kingdom	ATX	Registered
	NEW COMPOSITION-EP-GB							
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03784388.3 1 551 464		21034665 Ireland	ATX	Registered
	NEW COMPOSITION-EP-IE							
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03794388.3 1 551 464		21034663 Italy	ATX	Registered
	NEW COMPOSITION-EP-IT							
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03794388.3 1 551 464		21034662 Netherlands	ATX	Registered
	NEW COMPOSITION-EP-NL							
Patent EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	03754388.3 1 551 464		21034660 Sweden	ATX	Registered
	NEW COMPOSITION-EP-SE							
Patent Normal	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-08-01	2006 1671		21020985 Norway	ATX	Pending
	NEW COMPOSITION-F-NO							
Patent Normal via PCT National Phase	MITRA MEDICAL AB	2009-11-26 2024-11-26	2004-11-26	2004 292833		21026311 Australia	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-AU							
Patent Normal via PCT National Phase	MITRA MEDICAL AB	2008-11-26 2024-11-26	2004-11-26	2 547 435		21026321 Canada	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-CA							
Patent Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-26	200480041118.3		21026320 China	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-CN							
Patent Normal via PCT National Phase	MITRA MEDICAL AB	2008-11-30 2024-11-26	2004-11-26	04800410.5		21026319 European Patent Office	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-EP							
Patent Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-26	1871/CHEN/2006		21026318 India	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-IN							

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Ren. date Duration	Filing date Reg. date	Appl. No Reg. No	File No Country	Handl by	Status
Patent	Normal via PCT National Phase		2004-11-26	2006-641102	21026317 Japan	DH	Pending
	MITRA MEDICAL AB						
Patent	Normal via PCT National Phase		2004-11-26	2006-7012885	21026314 Republic of Korea	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-JP						
	MITRA MEDICAL AB						
Patent	Normal via PCT National Phase		2004-11-26	PAJAJ2006/006009	21026316 Mexico	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-KR						
	MITRA MEDICAL AB						
Patent	Normal via PCT National Phase	2008-11-30 2024-11-26	2004-11-26	2006-2410	21026315 Norway	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-MX						
	MITRA MEDICAL AB						
Patent	Normal via PCT National Phase		2004-11-26	10596 012	21026312 United States of America	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-NO						
	MITRA MEDICAL AB						
Patent	Normal via PCT National Phase		2004-11-26	10596 012	21026312 United States of America	DH	Pending
	TARGETING OF ERB ANTIGENS-PC-US						
	MITRA MEDICAL AB						

[illegible]

**डॉ० राजेंद्र प्रसाद**

Biotech IgG AB  
Status List  
July 16, 2008

MIT NO.	SERIAL NO.	PATENT NO.	DESCRIPTION	STATUS	DATE	ISSUE
31000/3000.USA	08/798,413		Water Soluble Biotin Derivatives	ABANDONED	2/7/1997	
33700.003	09/519,998		Reagent for Conjugation to a Biomolecule	ABANDONED	3/5/2000	
33700.003.CON1	11/190,955	US 2005-0271673-A1	Trifunctional Reagent for Conjugation to a Biomolecule	PUBLISHED	7/28/2005	12/3/2005
33700WC004	09/881,213	US 2002-0159594	Biotin derivatives	PUBLISHED	6/15/2001	10/31/2002
33700WC005	09/750,280	US 2001-0023288	Trifunctional reagent for conjugation to a biomolecule	PUBLISHED	12/29/2000	9/20/2001
33700WC005.CON	11/516,419	US-2007-0071673-A1	Trifunctional reagent for conjugation to a biomolecule	PUBLISHED	9/5/2006	3/29/2007
033703.006	10/311,150		Reusable Extracorporeal Columns Loaded with Ligand-Dibiotin Conjugates	PUBLISHED	4/23/2003	3/18/2004
33700.009	10/538,868	US 2008-0222588-A1	Antilymphoma Targeting Agents with Effector and Affinity Functions Linked by a Trifunctional Reagent	PUBLISHED	6/10/2005	10/5/2006
33700.010	10/695,012		Targeting of ERS Antigens	PENDING	5/25/2005	
337XX	60/795,025		Macromolecule Conjugate	EXPIRED	1/1/2008	
MIT.01a*	9100142-0		A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purpose	ABANDONED	1/17/1991	
MIT.01	PCT/SE92/00020		A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purpose	PUBLISHED	1/15/1992	8/5/1992
MIT.01US	08/090,047	6,251,394	A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purpose	ISSUED	10/12/1993	6/26/2001
MIT.002	07/388,664		Method of Treatment with Medical Agents	ABANDONED	8/2/1989	

# Biotech IgG AB

## Status List

July 16, 2008

INVENTOR	SERIAL NO.	PATENT NO.	PUB. NO.	TITLE	STATUS	FILE	PUBL. DATE	ISSUE
MIT.02	07/562,009	5,474,772		Method of Treatment with Medical Agents	ISSUED	8/2/1990		12/12/1995
MIT.02.1	08/434,889	5,046,225		Method of Treatment with Medical Agents	ISSUED	5/4/1995		4/4/2000
MIT.03	09/689,421	6,723,318		Targeting of Biomolecules	ISSUED	10/12/2000		4/20/2004
PC-21007191	PCT/SE03/001949		WO 04/054615	Anti-Lymphoma Tagging Agents with Effector and Affinity Functions Linked by a Trifunctional Reagent	PUBLISHED	12/12/2003		
PC-21017441	PCT/SE04/001753		WO 05/051424	Targeting of ErbB Antigens	PUBLISHED	11/26/2004		
UNIV0029	60/011,321			Water Soluble Biotin Derivatives	EXPIRED	2/8/1996		
WV 4934-004	PCT/SE01/02231			A Method and a System for Enhanced In Vivo Clearances of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purpose	PENDING			

Patenter og patentansøgninger i navnet: Mitra Medical Technology AB

Chas. Hude ref.	Land	Ansøgningsnr.	Patentnr.	Udstedelsesdato	Udløb
72473	AU	17775/99	736826	15. November 2001	14. Januar 2001
72474	CA	2.318.316	2.318.316	10. april 2007	14. Januar 2001
72475	CN	99803802.4	99803802.4	4. august 2004	14. Januar 2001
72477	IL	137.302	137.302	21. februar 2006	14. Januar 2001
72478	JP	2000-539881		Under behandling. Ny officiel behandlingsskrivelse modtaget 14. juli 2008	14. Januar 2001
72479	NO	20003654	319819	19. September 2005	14. Januar 2001
72480	RU	2000121968	2215544	10. November 2003	14. Januar 2001
72481	US	600.446	6.558.543	6. maj 2003	14. Januar 2001
78064	AT	99900077.1	E 251.290	15. oktober 2003	14. Januar 2001
78065	BE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78066	CH	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78067	CY	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78068	DE	99900077.1	699 12 096.9	15. oktober 2003	14. Januar 2001
78069	DK	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78070	ES	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78071	FI	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78072	FR	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78073	GB	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78074	GR	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78075	IE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78076	IT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78077	LU	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78078	MC	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78079	NL	99900077.1	1049499	15. oktober 2003	14. Januar 2001

78080	PT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78081	SE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78082	AL	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78083	LT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78084	LV	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78085	MK	99900077.1	901219	15. oktober 2003	14. Januar 2001
78086	RO	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78087	SI	99900077.1	1049499	15. oktober 2003	14. Januar 2001